Association between food-specific immunoglobulin G4 antibodies in adults with self-reported signs and symptoms attributed to adverse reactions to foodstuffs
Loading...
Official URL
Full text at PDC
Publication date
2023
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI
Citation
Pantoja-Arévalo, L.; Gesteiro, E.; Matthias, T.; Urrialde, R.; González-Gross, M. Association between Food-Specific Immunoglobulin G4 Antibodies in Adults with Self-Reported Signs and Symptoms Attributed to Adverse Reactions to Foodstuffs. Biomedicines 2023, 11, 3335. https://doi.org/10.3390/biomedicines11123335
Abstract
Signs and symptoms attributed to adverse reactions to foodstuffs (ARFS) need tools for research and evaluation in clinical practice. The objectives of this study were (a) to evaluate the most frequent self-reported signs and symptoms attributed to ARFS in Spanish adults, (b) to determine the prevalence of food-specific IgG4 antibody reactions (AbRs), and (c) to investigate the association between self-reported ARFS symptomatology and food-specific IgG4 AbRs. Food-specific IgG4 AbRs against 57 common food and beverages (AESKUCARE-T2FA® in vitro point-of-care test kit, Aesku.Diagnostics GmbH, Germany) were determined in capillary blood samples of 205 volunteers living in the Region of Madrid (Spain). The most frequent self-reported signs and symptoms were related to skin (43%), digestive (41%), and nervous system (NS, 33%) problems. The prevalence of food-specific IgG4 AbRs was cow’s milk (73%), sheep’s milk (70%), casein (66%), and goat’s milk (56.10%). Positive IgG4 AbRs against tomato had a profile consisting of 3/4 of skin problems, more than half of digestive, and 2/5 of NS self-reported signs and symptoms. In conclusion, at least 1/3 of the studied sample reported skin, digestive, and NS signs and symptoms. The most frequent food-specific IgG4 AbRs were related to dairy. Skin problems were more frequent in positive tomato IgG4 AbRs.
Description
2023 Descuento MDPI
This research was funded by the ImFINE Research group’s own funds. Additional funding was from the Instituto de Salud Carlos III through CIBEROBN (CB12/03/30038), which is co-funded by the European Regional Development Fund. Lisset Pantoja-Arévalo is supported by the Universidad Politécnica de Madrid by means of a predoctoral contract (project number: P2011600273).